LETROZOLE and DYSPNOEA

Overview

DYSPNOEA is the #11 most commonly reported adverse reaction for LETROZOLE, manufactured by Novartis Pharmaceuticals Corporation. There are 2,838 FDA adverse event reports linking LETROZOLE to DYSPNOEA. This represents approximately 1.9% of all 148,871 adverse event reports for this drug.

Patients taking LETROZOLE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

DYSPNOEA is a less commonly reported adverse event for LETROZOLE, but still significant enough to appear in the safety profile.

Other Side Effects of LETROZOLE

In addition to dyspnoea, the following adverse reactions have been reported for LETROZOLE:

• FATIGUE — 7,159 reports
• NAUSEA — 5,258 reports
• NEUTROPENIA — 4,896 reports
• DIARRHOEA — 4,460 reports
• MALIGNANT NEOPLASM PROGRESSION — 4,255 reports
• ARTHRALGIA — 3,802 reports
• WHITE BLOOD CELL COUNT DECREASED — 3,678 reports
• ALOPECIA — 3,583 reports
• PAIN — 2,959 reports
• ASTHENIA — 2,852 reports

Other Drugs Associated with DYSPNOEA

The following drugs have also been linked to dyspnoea in FDA adverse event reports:

Does LETROZOLE cause DYSPNOEA?

DYSPNOEA has been reported as an adverse event in 2,838 FDA reports for LETROZOLE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is DYSPNOEA with LETROZOLE?

DYSPNOEA accounts for approximately 1.9% of all adverse event reports for LETROZOLE, making it a notable side effect.

What should I do if I experience DYSPNOEA while taking LETROZOLE?

If you experience dyspnoea while taking LETROZOLE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages